Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: rationale for new antithrombotic agents.
Moscucci
Mauro
M
Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA.
D000367:Age Factors; D015906:Angioplasty, Balloon, Coronary; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000191:economics; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000191:economics* / Q000209:etiology*; D019106:Postoperative Hemorrhage / Q000188:drug therapy / Q000191:economics* / Q000209:etiology*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D005343:Fibrinolytic Agents